# Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

> **NCT06508138** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 24 (estimated)

## Conditions studied

- HPV 16 Infection
- HPV-Related Carcinoma
- Recurrence
- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus

## Key facts

- **NCT ID:** NCT06508138
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-10-18
- **Primary completion:** 2027-04-18
- **Final completion:** 2027-10-18
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508138, "Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06508138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*